In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

University of Colorado

https://www.cu.edu/

Latest From University of Colorado

Ireland, Belgium And The Netherlands Withdraw From Libmeldy Gene Therapy Pricing Talks

The BeNeLuxA medicines access coalition has terminated pricing talks with Orchard over its gene therapy Libmeldy.

Europe Belgium

Bold Plans Pivotal GI Cancer Studies After Phase II Success

The private Canadian biotech is advancing a first-in-class GRP78 inhibitor into Phase III studies in gastrointestinal cancers after interim Phase II data suggested potential to improve upon on standard-of-care efficacy.

Clinical Trials Cancer

Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases

EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.

Financing Business Strategies

Pharming’s Portfolio Grows As Ultra-Rare Disease Drug Joenja Is Approved

The first ever approval for ultra-rare immunodeficiency disease APDS gives Pharming its second product on the market but patient diagnosis will be a major challenge.

Commercial Companies
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register